Bright Minds Biosciences Inc. DRUG
Bright Minds Biosciences Inc. (Nasdaq: DRUG) is a CNS/neurology/psychiatry drug developer. Its lead program, BMB-101, is in Phase 2 for drug-resistant epilepsies (absence epilepsy, developmental epileptic encephalopathy); Prader-Willi syndrome.
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| BMB-101 (5-HT2C Gq-biased agonist) BREAKTHROUGH study | absence epilepsy and DEE | small molecule | Phase 2 |
| BMB-101 exploratory study | Prader-Willi syndrome | small molecule | Phase 2 |
| BMB-105 (5-HT2C agonist) | Prader-Willi syndrome | small molecule | Pre-clinical |
| BMB-202 (5-HT2A agonist) | depression / neuropsychiatric | small molecule | Pre-clinical |
| BMB-201 (5-HT2A/2C agonist prodrug) | headache / pain | small molecule | Pre-clinical |
Recent results and decisions
- Jan 6, 2026positive Open-label Phase 2 absence cohort (n=11 evaluable) met primary endpoint with 73.1% median reduction in absence seizures >=3s, p=0.012.
73.1% median reduction in the number of absence seizure ≥3s. p = 0.012 (Wilcoxon Signed Rank Test)
Filing
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 2 CNS/neurology/psychiatry companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.